Biotech · Private company · Rochester, NY, US
Edi Therapeutics LLC
Track this companyFree. Adds Edi Therapeutics LLC to your Dealase workspace and tells you when its record changes.
Clinical trials0None registered
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
NIH awards3
- Chimectin as a novel wound biologic for xylazine-induced tissue injuryFiscal year 2026 · $274.2KNIH RePORTER 1R41DA064269-01 · fetched Nov 12, 2026
- Development of EDI-239382, a novel IRAK4 inhibitor to control inflammation driven metastasis, immune dysfunction and chemoresistance niche in ovarian tumors.Fiscal year 2026 · $377.5KNIH RePORTER 1R43CA309899-01 · fetched Nov 12, 2026
- Fibronectin matrix mimetic, Chimectin as a first-in-class therapeutic for chronic wound healingFiscal year 2024 · $388.2KNIH RePORTER 1R43DK138579-01A1 · fetched Nov 12, 2026